|Bid||21.00 x 1200|
|Ask||26.37 x 1100|
|Day's Range||23.34 - 24.95|
|52 Week Range||21.45 - 34.00|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.67|
Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the first patient has been dosed in the Phase 1/2 clinical trial of RP-3500, a potent and selective oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase) for the treatment of solid tumors with specific genome instability-related genomic alterations including those in ATM gene (ataxia teleangectasia mutated kinase). The multi-center trial will enroll patients with advanced solid tumors of any histology that harbor gene alterations that suggest sensitivity to ATR inhibition as discovered by Repare’s proprietary SNIPRx® platform. Dosing follows acceptance by the U.S. Food and Drug Administration (FDA) of the Company’s investigational new drug (IND) application earlier this month.
H1 2020 Canadian IPO - CSE leads in number of non-CPC/SPAC IPOs (88%), GFL IPO accounts 77% of IPO amount
Oak Investment Partners disclosed a large stake in digital-content provider Leaf Group. Forma Therapeutics said it owns more than nine million shares of biopharmaceutical firm Forma.